This inventor holds 1 USPTO granted patent. Top assignees: Bristol-Myers Squibb Compnay, Rigel Pharmaceuticals, Incorporated. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3,745 
1 out of 492 
Years Active: 2022
Title: Chetan Padmakar Dame: Innovator in TGF-beta Inhibitors
Introduction
Chetan Padmakar Dame is a notable inventor based in Orange, Connecticut. He has made significant contributions to the field of pharmaceuticals, particularly in the development of TGF-beta inhibitors. His work has the potential to impact the treatment of various diseases by blocking TGF-beta signaling.
Latest Patents
Chetan holds a patent for TGF-beta inhibitors, which includes imidazole and thiazole compounds. The patent discloses pharmaceutical compositions and methods of use, with one embodiment featuring a compound that inhibits TGF-beta. This compound can be utilized to treat diseases by effectively blocking TGF-beta signaling.
Career Highlights
Throughout his career, Chetan has worked with prominent companies in the pharmaceutical industry. He has been associated with Rigel Pharmaceuticals, Incorporated and Bristol-Myers Squibb Company, where he has contributed to innovative research and development efforts.
Collaborations
Chetan has collaborated with several professionals in his field, including Todd M Kinsella and Marina Gelman. These collaborations have likely enhanced his research and development capabilities, leading to advancements in his work.
Conclusion
Chetan Padmakar Dame is a distinguished inventor whose work on TGF-beta inhibitors showcases his commitment to advancing pharmaceutical science. His contributions have the potential to lead to significant improvements in disease treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile